Capillary Blood Accuracy

Launched by ENTIA LTD · Aug 5, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "Capillary Blood Accuracy," is studying a new blood testing device called Entia Liberty, which can analyze blood using a small sample taken from a finger prick. The goal is to see how accurate the results from this device are compared to the traditional blood tests that take blood from the arm or other sites. This research is important for cancer patients who are receiving treatment and need regular blood tests to monitor their health.

To participate in the trial, individuals must be at least 18 years old and currently undergoing cancer treatment that involves systemic anti-cancer therapy. They should also be having routine blood tests as part of their care. Participants will need to provide written consent and meet specific criteria regarding their blood cell counts. The study is not yet recruiting participants, but once it begins, those who qualify will help researchers understand if the Entia Liberty device can offer a convenient and accurate way to test blood.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years old at the time of study entry
• • Patients undergoing systemic anti-cancer therapy (SACT)
• • Patients capable of providing written informed consent
• • Patients undergoing routine Full Blood Count (FBC) laboratory blood tests as part of the standard of care
• Additional inclusion criteria:
• • Phase 1 (Longitudinal, low count data): Neutrophil Count ≤ 1.0 x109/L within 24 hours preceding consenting
• • Phase 2 (Low count data): Neutrophil Count ≤ 1.5 x109/L within 24 hours preceding consenting
• Exclusion Criteria:
• • History or current diagnosis of haematological malignancy
• • Inadequate use and understanding of the English language, requiring a translator